


# Al-Razi University Journal for Medical Sciences



## RUJMS

ISSN No. 2616-6143

Volume (2) Issue (2) December 2018



مرخصة من وزارة التعليم العالي والبحث العلمي  
بقرار وزاري رقم ( 57 ) لسنة 2018م

## RUJMS

Published by Al-Razi University

Bianual Refereed Journal

All Rights Reserved for Al-Razi University

| Editor in Chief                 | Nationality | Degree              |
|---------------------------------|-------------|---------------------|
| Prof. Dr. Nabil Ahmed Al-Rabeei | Yemen       | Professor           |
| Editor Manager                  | Nationality | Degree              |
| Dr. Rashad Al-Namer             | Yemen       | Associate Professor |

## Editorial Board Members

| No  | Editorial board members        | Nationality | Degree              |
|-----|--------------------------------|-------------|---------------------|
| 1.  | Prof. Dr. Abdulsalam.M. Dallak | Yemen       | Professor           |
| 2.  | Prof. Dr. Abduljalil D. Ghaleb | Yemen       | Professor           |
| 3.  | Prof. Dr. Mohammed Abdulhaleem | Yemen       | Professor           |
| 4.  | Prof. Dr. Mohammed Aissa       | Yemen       | Professor           |
| 5.  | Prof. Dr. Ahmed Al-Sobati      | Yemen       | Professor           |
| 6.  | Dr. Abdulhameed Al-Thifani     | Yemen       | Associate Professor |
| 7.  | Dr. Nouradden Al-Jaber         | Yemen       | Associate Professor |
| 8.  | Dr. Shatha Hassan Yassin       | Yemen       | Associate Professor |
| 9.  | Dr. Sadeq Hassan Al-Sheraji    | Yemen       | Associate Professor |
| 10. | Dr. Ahmed Ali Abdulateef       | Yemen       | Associate Professor |
| 11. | Dr. Abdulmajid Alssaifi        | Yemen       | Associate Professor |

## Advisory Board

| No | Advisory Board         | Nationality | Degree              |
|----|------------------------|-------------|---------------------|
| 1. | Dr. El Houcin Boidida  | Morocco     | Associate Professor |
| 2. | Dr. Yahia Cherrah      | Morocco     | Associate Professor |
| 3. | Dr. Abdulaziz Benjouad | Morocco     | Associate Professor |
| 4. | Dr. Abdellah Akil      | USA         | Associate Professor |
| 5. | Dr. Katim Alaoui       | Morocco     | Associate Professor |
| 6. | Dr. Arvinder Bahala    | India       | Associate Professor |
| 7. | Dr. David Tasala       | USA         | Associate Professor |

**Copyright of articles published in the RUJMS belong to the University of Al-Razi unless the work is subject to copyright.**

**Address: Al-Razi University - College of Medical Sciences**

**Telefax: +9671406760 P.O. Box:1152 Sana'a – Yemen**

**Website: <http://alraziuni.edu.ye/rujms/>**

**Designed by Eng. Osama Al-Moaina  
Ossamah245@yahoo.com**

**Misoprostol versus Oxytocin for the Prevention of Postpartum Haemorrhage among Women in Al-Thowrah Hospital, Sana'a City, Yemen**

Intisar Ali Mohammed\*

*\*Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Sana'a University**\*Corresponding author: Faculty of Medicine & Health Sciences, Sana'a University Yemen: email: intisarahmed126@yahoo.com***Abstract**

**Background:** PPH is the leading cause of direct maternal death in developing countries. PPH is a real complication that should be studied and dealt with seriously. **Aim:** To compare the safety and efficacy of rectal misoprostol versus intravenous oxytocin in preventing PPH. **Methods:** A randomized control study was done for 6 months from 1st of May to 31 of October 2017. In the labor room of the obstetric unit at AMGH in Sana'a. The subjects were included 98 women divided into two groups: group I included 51 women were received 600 µg (3 tablets) misoprostol rectally and 2ml saline in Ringers lactate intravenously as placebo. Group II: included 47 women were received 30IU intravenous oxytocin in Ringers lactate and two lactose tablets rectally as placebo. The collected data for every woman, Patient kept under close observation for 4 hours, for any vaginal bleeding, nausea, vomiting, fever, shivering and etc. Then estimated of blood loss and side effects of uterotonic drugs by direct observation. **Results:** Incidence of PPH in the misoprostol group 23.5% was more than that found in the oxytocin group 6.4% ( $p\text{-value} < 0.05$ ). Risk factors were not significantly different in the two groups, except the prior history of PPH which is more in group I. Side effects: Shivering was more incidences in group I, 54.9% than group II, and 4.3%. While nausea was found in one case 2.1% in group II and no case found in group I. Pyrexia and vomiting were not found in the two groups. Additional uterotonic TTT was used to prevent PPH, within 4 hours of observation: 17.6% of group I needed 3 tablets misoprostol rectally and 6.4% of group II needed 30IU oxytocin infusion was added to prevent PPH. **Conclusion:** Misoprostol 600µg given rectally is less effective to control the PPH in the management of the third stage labour.

**Keywords:** Safety; Efficacy; Postpartum haemorrhage; Misoprostol; Oxytocin**Introduction**

Postpartum hemorrhage (PPH) is one of the most important causes of maternal mortality<sup>1</sup>. PPH is a potential obstetric catastrophic contribute a major cause of maternal death. Every year, about 210 million women become pregnant. PPH is one of the major complications of pregnancy,

accounting for 14 million cases annually. Of these, it is estimated that around 140,000 women die, resulting in a case fatality rate of 1%<sup>1</sup> adequate attention to this complication can mean the difference between life and death<sup>2</sup> Maternal mortality is high in

developing countries. In Yemen, it represents 385/100000 of live birth which is very high incidence.

The major cause of it is PPH is a significant cause of maternal morbidity and mortality. Most PPH are caused by uterine atony and occur in the immediate postpartum period<sup>3</sup>. PPH is the leading cause of direct maternal death in developing countries. The incidence of postpartum hemorrhage may vary from less than 5% to more than 10%. The figures remain at least 100 times higher than those in developed countries<sup>4</sup>. Although risk factors may increase a woman's chances of developing postpartum hemorrhage, two-thirds of cases of PPH occur without any predisposing factors. Several drugs reduce postpartum hemorrhage by causing the uterus to contract. Ergot derivatives have been used for decades, although oxytocin is the drug of choice in some centers<sup>5</sup>. Prophylactic use of an oxytocic agent after delivery of the infant has been shown to reduce the incidence of postpartum haemorrhage by 40%.

The most common practice in the United States for the prevention of PPH is intravenous oxytocin administration after placental delivery<sup>6</sup>. Now 10 IU oxytocin is used also several prostaglandins are used as second or third line agents. These drugs, however, must be refrigerated to remain effective. Moreover, most uterotonics must be administered by injection, which requires sterile equipment and training in safe administration, prerequisites unavailable for most women delivering in low-income countries<sup>5</sup>.

Misoprostol was shown in several randomized controlled trials to be effective in preventing PPH because of its strong uterotonic effects. Moreover, misoprostol is inexpensive and easy to

administer<sup>6</sup>. Misoprostol, a prostaglandin E1 analog, is heat stable and can be administered orally, rectally, or sublingually. Oral and rectal misoprostol has been used for routine management of the third stage of labour.

The main side-effects have been shivering and pyrexia, which is dose-dependent. Physiological studies have also shown a more rapid onset of uterine contractions following syntometrine than misoprostol after delivery. Misoprostol has been widely recommended for the prevention of PPH when other methods are not available<sup>7,8</sup>. Community-based distribution of misoprostol in Indonesia reduced the perceived frequency of excessive bleeding and the need for emergency referral for PPH compared with data from a control area where misoprostol was not available<sup>8,9</sup>.

### **Aim of the study**

To compare the safety and efficacy of rectal misoprostol versus intravenous oxytocin in preventing PPH.

### **Subjects and Methods**

This study was carried out in the obstetric unit at Al-Thawrah Modern General Hospital (AGMH), Sana'a. The hospital is the largest public and referral hospital in Yemen, it receives all obstetric emergency cases referred from different locations. The department of obstetrics and gynaecology has all facilities that serve the patients including blood bank, laboratory and a well expert staff. A randomized clinical trial study was undertaken among women admitted to labor room in AGMH from 1 May to 31 October 2017. After taken detail history 98 women were divided into two groups (Group I included 51 women were given 3 tablets

misoprostol (600Mg) rectally +5ml saline in 500cc Ringer lactate after clamping of the umbilical cord, and group II included 47 women were given 30 IV oxytocin in 500cc Ringer lactate +2 lactose tablets rectally after clamped of the umbilical cord).

Additional uterotonic treatment was used to prevent PPH within 4 hours was recorded. The exclusion criteria were all women in active labor with gestational age  $\leq 34$  weeks, all women in active labour who hypersensitive to prostaglandin, any patient indication for caesarean and any patient might be her delivery ended by caesarean.

The inclusion criteria were the women with maternal age <20-35 years, gravidity, parity, special habits, ANC, gestational age  $\geq 34$  weeks, PET, APH, anemia, past history of PPH, twin pregnancy, polyhydramnios, patient on Mg So<sub>4</sub>, women in active labour without any contraindication for vaginal delivery, past history of PPH and previous history to caesarean. Detail history was taken from the patient regarding the inclusion criteria mentioned before. The patient keeps under close observation, fetal and maternal monitoring was done until the patient was delivered. Then patient who selected to given 3 tablets misoprostol (600Mg) rectally put in a group I, and 30 IV infusion oxytocin in group II. The placenta is delivered by Brandt –Androw method, a uterine massage done, placenta, perineum, and vagina were examined. Any tear or episiotomy was a stitch. Visual estimated of blood loss was made by the attending resident and the number of a sheet was changed, uterine massage was done every 10 minutes, vital signs checked every 30 minutes. The patient kept under close observation for 4 hours, for any vaginal bleeding, nausea, vomiting, fever, shivering and etc. Data were

analysed using SPSS version 19 for frequency and cross tabulation. Chi-square test was applied to compare the categorical variable among groups. P-value <0.05 was considered significant.

## Results

The majority of age among the two groups was between (20-25 years) 87.2% in group II, 83.3% in group I. and age >35 years old(11.8%) in group I and (10.6%) in group II. >20 years age represent 2.1% in group II and 2.0% in group I. The majority of cases were khat chewers in the two groups: 76.5% in group I and 68.1% in group II, while non-Khat chewers was 31.9% in group II and 23.5% in group I. As regards to smoking, the majority of cases were non- smokers in both groups 84.3 % in group I and 83% in group II, while smokers 17.0% in group II and 15.7 % in group I. The majority of cases were multipara in both groups (61.7%) in group II and 60.8% in group I), the next common was among primipara 29.8% in group II and 29.4% in group I. Most of the patients were gestational age between (37-40 weeks) 98% in group I and 97.9% in group II then >37 in 2.1% in group II and 2.0% in group I and most of the patients had regular ANC in both groups 60.8% in group I and 59.6% in group II, while 40.4% in group II and 39.2% in group I had irregular ANC.

Analysing risk factors of PPH in the two groups showed that 3 cases in each group had preeclampsia which represents 6%, while. MgSO<sub>4</sub> and anemia were found in one case in each group. Others risk factors were one case twin and one case polyhydramnios in group II, and no any case found in group I. The most common factor affecting the study was a prior history of PPH which was more

in group I 13.7% than 2.1% in group II. Risk factors were not significantly different in the two groups, except the prior history of PPH which is more in group I. Table 1.

As regards to the side effects of both drugs, the findings of the study showed that in group I, the most common side effect was found within 4 hours was shivering in 28 cases 54.9%, and nausea, vomiting, and pyrexia were not found in any case while .in group II: nausea was found in one case 2.1%, shivering in 2 cases 4.3%, and vomiting and pyrexia were not found

in any case. A significantly different in shaving was found, but not found in nausea among groups. Table 2.


The proportion of PPH (blood loss >500 ml) within 4 hours was more in the misoprostol group (23.5%) than in the oxytocin group (6.4%) with p-value<0.05. Figure 1. The additional uterotonic drug was used to prevent PPH, within 4 hours of observation showed that 17.6% of group I needed 3 tablets misoprostol rectally and 6.4% of group II needed 30IU oxytocin infusion was added to prevent PPH with p-value<0.05. Figure 2.

**Table1: Distribution of risk factors among both groups**


| Risk factors      | Group I |      | Group II |     | Chi-square | P-value |
|-------------------|---------|------|----------|-----|------------|---------|
|                   | F       | %    | F        | %   |            |         |
| PET               | 3       | 6    | 3        | 6   | -          | -       |
| Tocolytic Mgso4   | 1       | 2.0  | 1        | 2.1 | 0.005      | 0.941   |
| Anaemia           | 1       | 2.0  | 1        | 2.1 | 0.005      | 0.941   |
| Twins             | 0       | 0.0  | 1        | 2.1 | -          | -       |
| Poly -hydromnious | 0       | 0.0  | 1        | 2.1 | -          | -       |
| Prior Hx of P.PH  | 7       | 13.7 | 1        | 2.1 | 4.338      | 0.036   |

**Table 2: Side effects within 4 hours of observation among groups**

| Side effects | Group I   |             | Group II |            | P-value |
|--------------|-----------|-------------|----------|------------|---------|
|              | F.        | %           | F.       | %          |         |
| Nausea       | 0         | 0.0         | 1        | 2.1        | 0.295   |
| Shivering    | 28        | 54.9        | 2        | 4.3        | 0.000   |
| <b>Total</b> | <b>28</b> | <b>54.9</b> | <b>3</b> | <b>6.4</b> |         |



**Figure 1: The incidence of PPH among both groups**



**Figure 2: The additional uterotonic drugs to prevent PPH among groups**

### Discussion

In developing countries, PPH is regarded as one of the major causes of maternal mortality and morbidity<sup>10, 11</sup>. Consequently, the active management of the third stage of labour should be practiced along with the routine use of intravenous oxytocin. To add for oxytocin and to prevent postpartum hemorrhage misoprostol was chosen because it has similar advantages but with minimal side effects, low shelf life, inexpensive and easily available. It is easy to use and does not require special storage conditions (i.e., can be stored easily at room temperature; is thermostable and light stable; does not require specific conditions for transfer) and has a shelf life of several years. These advantages make it a useful drug in reducing the incidence of postpartum hemorrhage in developing countries.<sup>12,13,14,15,16</sup>

Our study showed that the proportion of PPH (blood loss >500 ml) was more in group I (23.5%) than group II (6.4%) which is going with the previous studies carried out in different countries under different studies.<sup>10,17,18</sup>

In Gerstein, Wing in California at 2001 the study SAS performed on 325 women. 154 women received 2 tablets (400µg) misoprostol rectally and 161

women received 20 IU oxytocin in Ringers' lactate intravenously, the incidence of PPH in misoprostol group 21% was more than oxytocin group 15%<sup>17</sup>, which is similar to our study.

In Turkia, 1606 women were randomly grouped to receive 10 IU oxytocin plus rectal misoprostol, Rectal Misoprostol, Oxytocin 10 IU, 10 IU oxytocin plus methylergometrine. Where the result of PPH was 9.8% in the group received only rectal misoprostol compared with less incidence of PPH 3.5% in the group received oxytocin and methylergometrine.<sup>18</sup>

In Blum et.al. (2010) 80% of women were 407 women received 800µg sublingual misoprostol and 402 women received 10 IU oxytocin intravenously. The two groups did not differ in baseline demographic characteristic (age, parity, Hb & education).<sup>19</sup> The incidence of PPH was similar in two groups (11% in misoprostol and 10% in oxytocin) this not going with our study, the possible explanation for that is the small sample size, and less dose of misoprostol was used in our study.<sup>19</sup>

A study done in South Africa compared a combination of intramuscular syntometrine injection and oxytocin infusion to rectal misoprostol and found that those who



received misoprostol had a statistically significant reduction in bleeding and further medical cointerventions to control the bleeding (6% versus 34%)<sup>20</sup>.

In study performed by Karkanis et al. (2002)<sup>20</sup> among 240 women who randomly received 400 micrograms rectal misoprostol after delivery of the infant or parenteral oxytocin (5 units intravenously or 10 units intramuscularly) with the delivery of the anterior shoulder. No difference in Hb was observed between the groups and also the duration of the third stage of labor did not differ between the two groups. Those criteria are not considered in our study. In our study, No severe blood loss had occurred in both groups, these findings were similar to Winikoff study<sup>21</sup>. The change Hb concentration is not involved<sup>21</sup>.

Winikoff et al (2009)<sup>21</sup>, in his study: the total number of women was 978; 488 women received 800µg sublingual misoprostol and 490 women received 40 IU oxytocin IV. The incidence of severe blood loss was rare ≤ 1% of women in both groups, bleeding was controlled in 90% in misoprostol group and 96% in oxytocin group within 20 minutes additional blood loss was 30% in misoprostol and 17% in oxytocin groups.

Investigation for the WHO concluded that 600µg of oral misoprostol is less effective than parenteral oxytocin in minimizing blood loss as defined by the incidence of discrete outcome (Measured blood loss >1000 ml) or use of additional uterotonics<sup>21</sup>

Regarding the side effects, the shivering was more frequent in group I, 54.9% as compared with 4.3% in group II. This result was similar to other studies<sup>9,19, 22, 23,24</sup>. No, any cases found with nausea, vomiting, and pyrexia with misoprostol group and

only one case with nausea 2.1% in the oxytocin group. The result of pyrexia was different from other studies<sup>9,19,22,23,24</sup>. A study of 800µg oral misoprostol compared with IM Oxytocin was found a higher rate of shivering and fever with misoprostol than oxytocin<sup>25</sup>. In a group, I more uterotonic drug than group II was needed. misoprostol tablets rectally were given to group I in 17.6%, while IV infusion oxytocin was given to group II in 6.4%. This result similar to other studies<sup>17, 18</sup>.

### **Conclusion**

Misoprostol 600µg given rectally is less effective to control the PPH when utilized as a pharmacologic agent in active management of the third stage labor, as measured by visual estimation with 4 hours. The usual side effects of shivering were noted frequently. Oxytocin still the effective treatment of prevention of PPH.

### **Recommendations**

A number of measurements can be done to determine the possible risk factors of PPH and this implies implementation of a number of measurements were including: 1) Antenatal care visits for follow up of pregnancy to predict cause at high risk for PPH and manage it accordingly, 2) Most PPH can be avoided by delivery of patients at hospital and every effort should be made to decrease blood loss, 3) The staff should be qualified & have good training for active management of the third stage of labor to decrease incidence of PPH, 4) Improvement in health care services and increase the number of blood banks by the Ministry of health allowed more supplies of blood to patients.

### **References**

1. Nama V, Karoshial, kakumani v, The single unit transfusion in postpartum haemorrhage, A new perspective, *Int j Fertile women Med*, 2006;51(2):58-63
2. Reynders Fc, SentinL, Tjalma W, Jacquemyn Y, postpartum hemorrhage: Practical approach to a life-threatening complication, *clin Expobstel Caynect* 2006; 33(2) 81-4
3. Karen L. Maughan., Steven W. Heim. M.S.P.H., and Sim S. Galazka, M.D. Preventing Postpartum Hemorrhage: Managing the Third Stage of Labor. *Am Fam Physician* 2006;73:1025
4. Sachs BP, Brown DAJ, Driscoll SG, et al. Haemorrhage, infection toxemia and cardiac diseases, 1954-1985. Causes for their declining role in maternal mortality. *American Journal Public Health* 1988; 78: 671-75.
5. Cohen, et al. Postpartum uterine hemorrhage 4th edition, Williams and Wilkins. Baltimore. 1991; 1132-41.
6. Tammy S. Gerstenfeld, DO, and Deborah A. Wing, Rectal G misoprostol versus intravenous oxytocin for the prevention of postpartum hemorrhage after vaginal delivery *Am J Obstet Gynecol* 2001; 185: 878-82.
7. Nellore V, Mittal S, Dadhwal V. Rectal misoprostol versus 15-methyl prostaglandin F2  $\alpha$  for the prevention of postpartum hemorrhage. *Int J of Gynecology and Obstetrics* 2006; 94, 45-46.
8. Justus Hofmeyr G, Sandra Ferreira, Cheryl Nikodem V, Lindeka Mangesi, Mandisa Singata Misoprostol for treating postpartum hemorrhage: a randomized controlled trial *BMC Pregnancy Childbirth*. 2004; 4: 16.
9. Lars Høj, Placido Cardoso, Birgitte Bruun Nielsen, et al. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomized double-blind clinical trial *BMJ* 2005; 331:723,
10. Nasr, shahin AY, Elsamman AM, ZAKaherah MS, Shaaban OM. Rectal Misoprostol versus intravenous oxytocin for prevention of postpartum heamorrhage *Int J gyneacolobstet* 2009; 105(3): 344-7.
11. Gulmezoglu, A. M., Villar, J., Ngoc, N. T., Piaggio, G., Carroli, G., Adetoro, L.. WHO multicentre randomised trial of misoprostol in the management of the third stage of labor. *The Lancet*, 2001; 358, 689-695.
12. Kararli T, Catalano T, Needham TE, et al. Mechanism of misoprostol stabilization in hydroxypropyl methylcellulose. *Adv Exp Med Biol* 1991; 302: 275-89.
13. Gaud HT, Connors KA. Misoprostol dehydration kinetics in aqueous solution in the presence of hydroxypropylmethyl cellulose. *J Pharm Sci* 1992; 81: 145-8.
14. Mansouri, H. A., & Alsahly, N. Rectal versus oral misoprostol for active management of the third stage of labor: A randomized controlled trial. *Archives of Gynecology and Obstetrics*. 2010.
15. Ayyad I, Omar AA. Prevention of postpartum hemorrhage by rectal misoprostol. A randomized controlled trial. *Middle East Journal of Family Medicine*, 2004; 5 (5).
16. Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose-related shivering and pyrexia in the third stage of labor. The whocollaborative trial of misoprostol in the management of the third stage of labour. *Br J Obstet Gynecol* 1999; 106:304-8.
17. Gerstenfeld TS, Wing DA. Rectal misoprostol versus intravenous oxytocin for the prevention of postpartum hemorrhage after vaginal delivery. *Am J Obstet Gynecol* 2001; 185:878-82.
18. Caliskan E, Meydanli MM, Dilbaz B, Aykan B, Sonmezer M, Haberal A. Is rectal misoprostol really effective in the treatment of the third stage of labor? A randomized controlled trial. *Am J Obstet Gynecol* 2002; 187:1038-45?
19. Blum, J., Winikoff, B., Raghavan, S., Dabash, R., Ramadan, M. C., Dilbaz,

- B., et al. Treatment of postpartum haemorrhage with misoprostol versus oxytocin in women receiving prophylactic oxytocin: A double-blind, randomized, non-inferiority trial. *The Lancet*, 2010; 375, 217-223.
20. Karkanis SG, Caloia D, Salenieks ME, Kingdom J, Walker M, Meffe F, et al. Randomized controlled trial of rectal misoprostol versus oxytocin in third stage management. *J Obstet Gynecol Can* 2002; 24:149–54.
  21. Winikoff, B., Dabash, R., Durocher, J., Darwish, E., Ngoc, N. T., Leon, W., et al. Treatment of post-partum hemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labor: A double-blind, randomized, non-inferiority trial. *The Lancet*. 2009; 375, 210-216.
  22. Derman, R. J., Kodkany, B. S., Goudar, S. S., Naik, V. A., Bellad, M. B., Patted, S. S., et al. Oral misoprostol in preventing postpartum hemorrhage in resource-poor communities: A randomized controlled trial. *The Lancet*. 2006; 368, 1248-1253.
  23. WHO. Clarifying WHO position on misoprostol use in the community to reduce maternal death. Retrieved November 15, 2010, from World Health Organization:[http://www.who.int/reproductivehealth/publications/maternal\\_perinatal\\_health/rhr\\_10\\_11/en/index.html](http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/rhr_10_11/en/index.html)
  24. Oboro, V. O., &Tabowei, T. O. A randomized controlled trial of misoprostol versus oxytocin in the active management of the third stage of labor. *Journal of Obstetrics and Gynaecology*. 2003; 13-16.
  25. Khan, R.-U., El-Refaey, H., Sharma, S., Sooranna, D., & Stafford, M. Oral, rectal, and vaginal pharmacokinetics of misoprostol. *The American College of Obstetricians and Gynecologists*. 2004;103(5), 866-870.

## المقارنة بين ميسوبروستول وأوكسيتوسين في الوقاية من النزف التالي للولادة بين النساء في مستشفى الثورة، مدينة صنعاء، اليمن

### ملخص

**الخلفية:** يُعتبر النزف التالي للولادة (PPH) السبب الرئيسي للوفاة المباشرة للأمهات في البلدان النامية. يُعد النزف التالي للولادة مضاعفة حقيقية يجب دراستها والتعامل معها بجدية. **الهدف:** مقارنة سلامة وفعالية ميسوبروستول عن طريق المستقيم مقابل أوكسيتوسين عن طريق الوريد في الوقاية من النزف التالي للولادة. **الطرق:** أُجريت دراسة عشوائية مضبوطة لمدة 6 أشهر من 1 مايو إلى 31 أكتوبر 2017 في غرفة الولادة بوحدة التوليد في مستشفى الثورة بمدينة صنعاء. شملت الدراسة 98 امرأة قُسمن إلى مجموعتين: المجموعة الأولى شملت 51 امرأة تلقت 600 ميكروغرام (3 أقراص) من ميسوبروستول عن طريق المستقيم و2 مل من محلول ملحي في رينجر لاكتات عن طريق الوريد كعلاج وهمي. المجموعة الثانية شملت 47 امرأة تلقت 30 وحدة دولية من أوكسيتوسين عن طريق الوريد في رينجر لاكتات وقرصين من اللاكتوز عن طريق المستقيم كعلاج وهمي. تم جمع البيانات لكل امرأة ووضع المرضى تحت المراقبة الدقيقة لمدة 4 ساعات لملاحظة أي نزيف مهبل، غثيان، قيء، حمى، ارتعاش، إلخ. ثم تم تقدير فقدان الدم والآثار الجانبية للأدوية القابضة للرحم من خلال الملاحظة المباشرة. **النتائج:** كانت نسبة حدوث النزف التالي للولادة في مجموعة الميسوبروستول 23.5% أكثر من تلك التي وُجدت في مجموعة الأوكسيتوسين 6.4% (قيمة  $P < 0.05$ ). لم تكن عوامل الخطر مختلفة بشكل كبير بين المجموعتين، باستثناء التاريخ السابق للنزف التالي للولادة الذي كان أكثر في المجموعة الأولى. الآثار الجانبية: كان الارتعاش أكثر حدوثاً في المجموعة الأولى بنسبة 54.9% مقارنةً بالمجموعة الثانية بنسبة 4.3%. بينما وُجدت حالة واحدة من الغثيان بنسبة 2.1% في المجموعة الثانية ولم توجد أي حالة في المجموعة الأولى. لم تُسجل حالات حمى أو قيء في المجموعتين. تم استخدام أدوية قابضة للرحم إضافية للوقاية من النزف التالي للولادة خلال 4 ساعات من المراقبة: 17.6% من المجموعة الأولى احتاجت إلى 3 أقراص ميسوبروستول عن طريق المستقيم و6.4% من المجموعة الثانية احتاجت إلى إضافة 30 وحدة دولية من تسريب الأوكسيتوسين للوقاية من النزف التالي للولادة. **الاستنتاج:** ميسوبروستول بجرعة 600 ميكروغرام عن طريق المستقيم أقل فعالية في السيطرة على النزف التالي للولادة في إدارة المرحلة الثالثة من الولادة.